PR Newswire
NEW YORK
,
Feb. 15, 2022
/PRNewswire/ — The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB) alleging that the Company violated federal securities laws.
Class Period:
June 7, 2021
to
January 11, 2022
Lead Plaintiff Deadline:
April 8, 2022
No obligation or cost to you.
Learn more about your recoverable losses in BIIB:
https://www.kleinstocklaw.com/pslra-1/biogen-inc-loss-submission-form-2?id=23673&from=4
Biogen Inc. NEWS – BIIB NEWS
CLASS ACTION CASE DETAILS:
The filed complaint alleges that Biogen Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) there was a significant, undisclosed lobbying campaign between Biogen and the Food and Drug Administration (“FDA”) that was instrumental in the decision to file and approve Aduhelm, a drug being developed to treat Alzheimer’s disease; 2) the Phase III ENGAGE study demonstrated that Aduhelm failed to achieve a clinical benefit to Alzheimer’s patients; 3) ENGAGE was a failed study from which Biogen concluded not to seek FDA approval for Aduhelm in 2019; and 4) defendants misled investors as to the way in which approval was achieved, that the clinical data did not support a clinical benefit by taking Aduhelm and that side-effects were dangerous and serious.
WHAT THIS MEANS TO YOU AS A SHAREHOLDER:
If you have suffered a loss in Biogen you have until
April 8, 2022
to petition the court for lead plaintiff status. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
NO COST TO YOU:
If you purchased Biogen securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.
HOW TO PROTECT YOUR FINANCIAL INTERESTS:
For additional information about the BIIB lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link:
https://www.kleinstocklaw.com/pslra-1/biogen-inc-loss-submission-form-2?id=23673&from=4
ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY
10118
[email protected]
Telephone: (212) 616-4899
www.kleinstocklaw.com
View original content:
https://www.prnewswire.com/news-releases/biib-alert-the-klein-law-firm-announces-a-lead-plaintiff-deadline-of-april-8-2022-in-the-class-action-filed-on-behalf-of-biogen-inc-shareholders-301481724.html
SOURCE The Klein Law Firm
